Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT TBI and Cyclophosphamide Prior to Autologous HSCT in Severe Systemic Sclerosis
NCT04380831Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in systemic sclerosis (SSc), sponsored by City of Hope. Primary endpoints: Mean lung dose at 100 days and Mean kidney dose at 100 days. Started Feb 2022; status: active, not recruiting.
02
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT04380831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380831.